Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Oncolys Seeks Marketing License for Regenerative Medicine in Japan
Oncolys BioPharma said on November 26 that it has filed for a marketing license for regenerative medicine products in Japan as it gears up for the regulatory submission of its oncolytic virus telomelysin.The Tokyo biotech is currently in discussions with…
To read the full story
Related Article
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- PI Telomelysin Trial for Esophageal Cancer Begins in US: Oncolys
December 8, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
BUSINESS
- PeptiDream Hits Milestone with Asahi Kasei Collaboration
December 10, 2025
- Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
- Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025
- SanBio Clears Hurdle for Akuugo Shipments, Heads to Reimbursement Talks
December 10, 2025
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…